Assessment of evidence for COVID-19-related treatments (21 March 2020)

Summary

The information contained in this evidence table is emerging and rapidly evolving because of ongoing research and is subject to the professional judgment and interpretation of the practitioner due to the uniqueness of each medical facility’s approach to the care of patients with COVID-19 and the needs of individual patients. It has been rpoduced by the US-based organisation, the American Society of Health-System Pharmacists (ASHP). ASHP provides this evidence table to help practitioners better understand current approaches related to treatment and care. ASHP has made reasonable efforts to ensure the accuracy and appropriateness of the information presented. However, any reader of this information is advised ASHP is not responsible for the continued currency of the information, for any errors or omissions, and/or for any consequences arising from the use of the information in the evidence table in any and all practice settings.

Any reader of this document is cautioned that ASHP makes no representation, guarantee, or warranty, express or implied, as to the accuracy and appropriateness of the information contained in this evidence table and will bear no responsibility or liability for the results or consequences of its use.

Public access to AHFS Drug Information® (https://www.ahfscdi.com/login) is available for the next 60 days with the username "[email protected]" and password "covid19." ASHP's patient medication information is available at http://www.safemedication.com/.